{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:43:57Z","timestamp":1779907437874,"version":"3.53.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":256,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Intracerebral haemorrhage (ICH) is an important complication of direct oral anticoagulation (DOAC) therapy, where risks and prognosis are potentially modified by effective blood pressure (BP) control, both in the acute phase and for secondary prevention. Herein, we review BP management in the context of general anticoagulation associated ICH and specifically in DOAC-ICH, considering current evidence and highlighting outstanding questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Narrative review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>Pooled analyses of major trials of BP lowering in acute ICH patients without anticoagulants demonstrate a reduction in the risk of haematoma expansion. As anticoagulant-associated ICH patients tend to be older, have more co-morbidities, and larger haematomas at baseline with a greater risk of expansion, the risks and benefits of intensive BP lowering treatment might both be higher. Small observational studies of DOAC-ICH patients suggest that lower achieved BP is associated with less expansion, lower mortality, and better functional outcomes. Care bundles including both anticoagulant reversal and intensive BP lowering might reduce the risk of death and disability in DOAC-ICH. Optimal control of BP in survivors of ICH reduces the risk of both ischaemic and haemorrhagic stroke but whether this modulates the risks and benefits of restarting a DOAC is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Limited evidence suggests that BP should be well managed in DOAC-ICH patients, in the same way as ICH patients not on anticoagulants, both in the hyperacute phase and for secondary prevention. Hypothetical differences in the effects of BP lowering treatment in DOAC-ICH need to be tested in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873231208544","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:00:24Z","timestamp":1747897224000},"page":"46-55","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Importance of blood pressure lowering in patients with direct oral anticoagulant-associated intracerebral haemorrhage in the acute phase and for secondary prevention"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-3846","authenticated-orcid":false,"given":"Adrian R","family":"Parry-Jones","sequence":"first","affiliation":[{"name":"Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & University of Manchester, Manchester, UK 1"},{"name":"Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-3623","authenticated-orcid":false,"given":"Tom J","family":"Moullaali","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK 3"},{"name":"Department of Clinical Neurosciences, NHS Lothian, Edinburgh, UK 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4312-4778","authenticated-orcid":false,"given":"Else C","family":"Sandset","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stroke Unit, Oslo University Hospital, Oslo, Norway 5"},{"name":"The Norwegian Air Ambulance Foundation, Oslo, Norway 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan I","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-4863","authenticated-orcid":false,"given":"Craig S","family":"Anderson","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia 8"},{"name":"The George Institute China, Beijing, P.R. China 9"},{"name":"Neurology Department, Royal Prince Alfred Hospital, Sydney Health Partners, Sydney, NSW, Australia 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-8222","authenticated-orcid":false,"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[{"name":"Departments of Neurology, Klinikum Frankfurt H\u00f6chst and Heidelberg University Hospital, Frankfurt, Germany 11"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026012113080743100_bibr1-23969873231208544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/6707985","article-title":"Time Trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States","volume":"2022","author":"Vora","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2026012113080743100_bibr2-23969873231208544","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJMc1112500","article-title":"Apixaban versus warfarin in Atrial Fibrillation","volume":"366","author":"Granger","year":"2012","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr3-23969873231208544","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr4-23969873231208544","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr5-23969873231208544","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr6-23969873231208544","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ana.26267","article-title":"Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation","volume":"91","author":"Polymeris","year":"2022","journal-title":"Ann Neurol"},{"key":"2026012113080743100_bibr7-23969873231208544","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr8-23969873231208544","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/jcm11061596","article-title":"Increased prognostic yield by combined assessment of Non-Contrast computed tomography markers of antithrombotic-related spontaneous intracerebral hemorrhage expansion","volume":"11","author":"Katsanos","year":"2022","journal-title":"J Clin Med"},{"key":"2026012113080743100_bibr9-23969873231208544","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-023-00424-7","article-title":"Intracerebral haemorrhage","volume":"9","author":"Puy","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026012113080743100_bibr10-23969873231208544","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr11-23969873231208544","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr12-23969873231208544","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMoa1214609","article-title":"Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage","volume":"368","author":"Anderson","year":"2013","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr13-23969873231208544","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: A Guideline for healthcare professionals from the American Heart Association\/American Stroke Association","author":"Hemphill","journal-title":"Stroke J Cereb Circ"},{"key":"2026012113080743100_bibr14-23969873231208544","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(23)00806-1","article-title":"The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial","volume":"402","author":"Ma","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"2026012113080743100_bibr15-23969873231208544","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"key":"2026012113080743100_bibr16-23969873231208544","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O\u2019Donnell","year":"2010","journal-title":"Lancet"},{"key":"2026012113080743100_bibr17-23969873231208544","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026012113080743100_bibr18-23969873231208544","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.0000000000012276","article-title":"Acute hypertensive response in patients with acute intracerebral hemorrhage: A Narrative Review","volume":"97","author":"Hawkes","year":"2021","journal-title":"Neurology"},{"key":"2026012113080743100_bibr19-23969873231208544","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1603460","article-title":"Intensive blood-pressure lowering in patients with acute cerebral hemorrhage","volume":"375","author":"Qureshi","year":"2016","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr20-23969873231208544","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(19)30196-6","article-title":"Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data","volume":"18","author":"Moullaali","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr21-23969873231208544","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp-2021-327195","article-title":"Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"93","author":"Moullaali","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113080743100_bibr22-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1177\/23969873211012133","article-title":"European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage","volume":"6","author":"Sandset","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026012113080743100_bibr23-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: A Guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026012113080743100_bibr24-23969873231208544","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41440-022-01092-y","article-title":"Three rules for blood pressure management in acute intracerebral hemorrhage: fast, intense and stable","volume":"46","author":"Arima","year":"2023","journal-title":"Hypertens Res"},{"key":"2026012113080743100_bibr25-23969873231208544","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(08)70069-3","article-title":"Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial","volume":"7","author":"Anderson","year":"2008","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr26-23969873231208544","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000351149","article-title":"Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial","volume":"36","author":"Graffagnino","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"2026012113080743100_bibr27-23969873231208544","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12028-008-9085-8","article-title":"Rapid blood pressure reduction in acute intracerebral hemorrhage: Feasibility and safety","volume":"8","author":"Koch","year":"2008","journal-title":"Neurocrit Care"},{"key":"2026012113080743100_bibr28-23969873231208544","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/STROKEAHA.111.000188","article-title":"The intracerebral hemorrhage acutely decreasing arterial pressure trial","volume":"44","author":"Butcher","year":"2013","journal-title":"Stroke"},{"key":"2026012113080743100_bibr29-23969873231208544","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1161\/STROKEAHA.119.026389","article-title":"Prehospital transdermal glyceryl trinitrate for ultra-acute intracerebral hemorrhage: data from the RIGHT-2 trial","volume":"50","author":"Bath","year":"2019","journal-title":"Stroke"},{"key":"2026012113080743100_bibr30-23969873231208544","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1474-4422(22)00333-7","article-title":"Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial","volume":"21","author":"van den Berg","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr31-23969873231208544","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.phrs.2018.02.026","article-title":"Acute blood pressure elevation: Therapeutic approach","volume":"130","author":"Salvetti","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026012113080743100_bibr32-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107644","article-title":"Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis","volume":"227","author":"Seifi","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"2026012113080743100_bibr33-23969873231208544","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"key":"2026012113080743100_bibr34-23969873231208544","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026012113080743100_bibr35-23969873231208544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.122.028336","article-title":"Antithrombotic treatment, prehospital blood pressure, and outcomes in spontaneous intracerebral hemorrhage","volume":"12","author":"Larsen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026012113080743100_bibr36-23969873231208544","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/jnnp-2016-313246","article-title":"Early blood pressure lowering in patients with intracerebral haemorrhage and prior use of antithrombotic agents: pooled analysis of the INTERACT studies","volume":"87","author":"Song","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113080743100_bibr37-23969873231208544","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.25546","article-title":"An intracerebral hemorrhage care bundle is associated with lower case fatality","volume":"86","author":"Parry-Jones","year":"2019","journal-title":"Ann Neurol"},{"key":"2026012113080743100_bibr38-23969873231208544","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00415-019-09536-1","article-title":"Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use","volume":"266","author":"Seiffge","year":"2019","journal-title":"J Neurol"},{"key":"2026012113080743100_bibr39-23969873231208544","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000047638","article-title":"Intracranial hemorrhage and oral anticoagulant treatment","volume":"11","author":"Neau","year":"2001","journal-title":"Cerebrovasc Dis"},{"key":"2026012113080743100_bibr40-23969873231208544","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1385\/NCC:5:3:197","article-title":"Location and outcome of anticoagulant-associated intracerebral hemorrhage","volume":"5","author":"Flaherty","year":"2006","journal-title":"Neurocrit Care"},{"key":"2026012113080743100_bibr41-23969873231208544","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2013.06.020","article-title":"Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location","volume":"332","author":"Ma","year":"2013","journal-title":"J Neurol Sci"},{"key":"2026012113080743100_bibr42-23969873231208544","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"key":"2026012113080743100_bibr43-23969873231208544","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/brain\/aws349","article-title":"Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study","volume":"136","author":"B\u00e9jot","year":"2013","journal-title":"Brain"},{"key":"2026012113080743100_bibr44-23969873231208544","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.35.7.943","article-title":"Anticoagulant-related intracerebral hemorrhage","volume":"35","author":"Kase","year":"1985","journal-title":"Neurology"},{"key":"2026012113080743100_bibr45-23969873231208544","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/01.STR.21.5.726","article-title":"Intracerebral hematomas during anticoagulant treatment","volume":"21","author":"Franke","year":"1990","journal-title":"Stroke"},{"key":"2026012113080743100_bibr46-23969873231208544","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.410160505","article-title":"The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study","volume":"16","author":"Wintzen","year":"1984","journal-title":"Ann Neurol"},{"key":"2026012113080743100_bibr47-23969873231208544","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.25342","article-title":"Neuroimaging and clinical outcomes of oral anticoagulant\u2013associated intracerebral hemorrhage","volume":"84","author":"Tsivgoulis","year":"2018","journal-title":"Ann Neurol"},{"key":"2026012113080743100_bibr48-23969873231208544","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2026012113080743100_bibr49-23969873231208544","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"MacMahon","year":"2001","journal-title":"Lancet"},{"key":"2026012113080743100_bibr50-23969873231208544","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.STR.0000106480.76217.6F","article-title":"Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial","volume":"35","author":"Chapman","year":"2004","journal-title":"Stroke"},{"key":"2026012113080743100_bibr51-23969873231208544","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke"},{"key":"2026012113080743100_bibr52-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000665","article-title":"Correction to: 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2026012113080743100_bibr53-23969873231208544","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113080743100_bibr54-23969873231208544","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2026012113080743100_bibr55-23969873231208544","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"5","author":"Perry","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012113080743100_bibr56-23969873231208544","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1474-4422(21)00075-2","article-title":"Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies","volume":"20","author":"Li","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr57-23969873231208544","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jama.2015.10082","article-title":"Association between blood pressure control and risk of recurrent intracerebral hemorrhage","volume":"314","author":"Biffi","year":"2015","journal-title":"JAMA"},{"key":"2026012113080743100_bibr58-23969873231208544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003599","article-title":"Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis","volume":"18","author":"Pinho-Gomes","year":"2021","journal-title":"PLoS Med"},{"key":"2026012113080743100_bibr59-23969873231208544","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(18)30145-5","article-title":"Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study","volume":"17","author":"Wilson","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr60-23969873231208544","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI\u2013neuropathology diagnostic accuracy study","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr61-23969873231208544","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/STROKEAHA.109.563932","article-title":"Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial","volume":"41","author":"Arima","year":"2010","journal-title":"Stroke"},{"key":"2026012113080743100_bibr62-23969873231208544","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S1474-4422(21)00264-7","article-title":"Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial","volume":"20","author":"Al-Shahi Salman","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr63-23969873231208544","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1474-4422(21)00298-2","article-title":"Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial","volume":"20","author":"Schreuder","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080743100_bibr64-23969873231208544","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/2396987320954671","article-title":"STudy of antithrombotic treatment after IntraCerebral haemorrhage: Protocol for a randomised controlled trial","volume":"5","author":"Larsen","year":"2020","journal-title":"Eur Stroke J"},{"key":"2026012113080743100_bibr65-23969873231208544","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/2396987320975724","article-title":"Prescription of blood pressure lowering treatment after intracerebral haemorrhage: prospective, population-based cohort study","volume":"6","author":"Bonello","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026012113080743100_bibr66-23969873231208544","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/HYPERTENSIONAHA.118.11139","article-title":"Effect of adherence to antihypertensive medication on the long-term outcome after hemorrhagic stroke in Korea","volume":"72","author":"Kim","year":"2018","journal-title":"Hypertension"},{"key":"2026012113080743100_bibr67-23969873231208544","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1212\/WNL.0b013e31822f0423","article-title":"Secondary preventive medication persistence and adherence 1 year after stroke","volume":"77","author":"Bushnell","year":"2011","journal-title":"Neurology"},{"key":"2026012113080743100_bibr68-23969873231208544","doi-asserted-by":"crossref","DOI":"10.3399\/bjgp16X685609","article-title":"Barriers to medication adherence for the secondary prevention of stroke: A qualitative interview study in primary care","volume":"66","author":"Jamison","year":"2016","journal-title":"Br J Gen Pract"},{"key":"2026012113080743100_bibr69-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(19)30343-2","article-title":"Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial","volume":"7","author":"Lung","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2026012113080743100_bibr70-23969873231208544","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.12.015","article-title":"Effectiveness of fixed dose combination medication ('polypills\u2019) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries","volume":"205","author":"Webster","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012113080743100_bibr71-23969873231208544","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr72-23969873231208544","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"New Engl J Med"},{"key":"2026012113080743100_bibr73-23969873231208544","first-page":"557","article-title":"Arterial hypertension","volume":"115","author":"Jordan","year":"2018","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2026012113080743100_bibr74-23969873231208544","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(89)90689-9","article-title":"Urapidil, a multiple-action alpha-blocking drug","volume":"64","author":"Prichard","year":"1989","journal-title":"Am J Cardiol"},{"key":"2026012113080743100_bibr75-23969873231208544","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00609752","article-title":"Pharmacokinetics and side-effects of clonidine","volume":"13","author":"Ker\u00e4nen","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2026012113080743100_bibr76-23969873231208544","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"key":"2026012113080743100_bibr77-23969873231208544","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00003088-200241070-00004","article-title":"Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines","volume":"41","author":"Frishman","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"2026012113080743100_bibr78-23969873231208544","first-page":"288","article-title":"Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent","volume":"5","author":"Angaran","year":"1986","journal-title":"Clin Pharm"},{"key":"2026012113080743100_bibr79-23969873231208544","article-title":"Esmolol","volume-title":"StatPearls","author":"Pevtsov","year":"2023"},{"issue":"1","key":"2026012113080743100_bibr80-23969873231208544","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000175050","article-title":"Pharmacokinetics and pharmacodynamics of amlodipine","volume":"80","author":"Abernethy","year":"2008","journal-title":"Cardiology"},{"key":"2026012113080743100_bibr81-23969873231208544","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.annemergmed.2008.04.025","article-title":"Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension","volume":"53","author":"Pollack","year":"2009","journal-title":"Ann Emerg Med"},{"key":"2026012113080743100_bibr82-23969873231208544","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00003088-198409030-00005","article-title":"Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate","volume":"9","author":"Schulz","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"2026012113080743100_bibr83-23969873231208544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198712010-00001","article-title":"Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations","volume":"12","author":"Bogaert","year":"1987","journal-title":"Clin Pharmacokinet"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873231208544","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873231208544","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/46\/64645550\/23969873231208544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/46\/64645550\/23969873231208544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:43Z","timestamp":1769018923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1_suppl\/46\/8268615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":83,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873231208544","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2025,4,1]]}}}